Please assess the completion status of the following clinical trial:

Trial Title: Linagliptin Versus Placebo in Type 2 Diabetic Patients With Inadequate Glycaemic Control on Metformin in Combination With Pioglitazone

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~1. Diagnosis of diabetes mellitus prior to informed consent~2. Patients treated with metformin and pioglitazone (therapy should be unchanged for 12 weeks)~3. Glycosylated haemoglobin A1 \>= 7.5% and \<= 10%~4. Age between 18 and less than 80~5. - Body Mass index less or equal to 45~Exclusion criteria:~1. Uncontrolled hyperglycaemia during run in period~2. Myocardial infarction, stroke or transient ischaemic accident within 3 months prior to informed consent~3. Impaired hepatic function~4. Gastric by pass surgery~5. Treatment with roziglitazone, GLP 1 analogues, DPP-4 inhibitors or insulin within 3 months prior to informed consent~6. Treatment with anti-obesity drugs~7. Current treatment with systemic steroids at the time of informed consent or change in dosage of thyroid hormones within 6 weeks prior to informed consent~8. Premenopausal women who are nursing or pregnant or are of child-bearing potential and are not practicing an acceptable method of birth control or do not plan to continue using this method during the trial

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 79 Years
- Healthy Volunteers: f

Study Arms:
- Linagliptin (Type: EXPERIMENTAL): Linagliptin tablets once daily
- Placebo (Type: PLACEBO_COMPARATOR): Placebo tablets once daily

Based on this trial design, predict the completion outcome and termination type (if applicable).